BALF mNGS for IPA in ICU
The clinical utility of metagenomic next-generation sequencing (mNGS) in immunocompromised critically ill patients with invasive pulmonary aspergillosis (IPA) remains poorly studied. Given the diagnostic challenges and high mortality associated with IPA in this population, further research on the use of mNGS for early diagnosis and targeted therapy is urgently needed. This study aims to further validate the clinical value of mNGS for the early diagnosis of IPA in this population and to explore its impact on prognosis.